Synthesis and in vitro Cytotoxic Anticancer Activity of Novel Copper Complexes of Substituted 1H-Benzimidazole

Synthesis and in vitro cytotoxic activity of novel copper complexes of substituted 1H-Benzimidazole. Promising entities for target- specific next-generation anticancer therapeutics are copper-based compounds. Instead, because of their large range of possible functionalization and coordination modes, benzimidazole scaffolds play an important role. Recently, metal complexes are being hybridized with various moieties to discover new drugs because of their beneficial attributes. Copper is good for synthesizing a metal complex among metals because of its endogenous, redox and DNA cleavage capacity, anti-cancer efficacy and selective permeability reported for cancer cells. In this study, first we synthesized a new series of benzimidazole ligands. Then we have synthesized a series of bidentate copper(II)Benzimidazole complex then characterized by various techniques such as Infrared spectroscopy, Nuclear magnetic resonance spectroscopy. Synthesized compounds further investigated for invitro anticancer activity on the human cell line by brine shrimp lethality bioassay. Cytotoxicity was calculated in terms of LC50. Cisplatin was taken as standard for the biological evaluation. In this study it was found that from synthesized 8 complexes the C6 complexes was more cytotoxic than cisplatin, where C3 was least toxic in comparison with standard drug cisplatin. Where complex C1, C2, C4, C5, C7, C8 were moderately cytotoxic as compared to cisplatin.